Cargando…

The Development Pathway for Biosimilar Biotherapeutics

Detalles Bibliográficos
Autor principal:	Zarbin, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PUBLISHED BY KNOWLEDGE E 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431720/ https://www.ncbi.nlm.nih.gov/pubmed/32864056 http://dx.doi.org/10.18502/jovr.v15i3.7444

Ejemplares similares

Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)

In vivo selection of novel biotherapeutics
por: Ruozi, Giulia, et al.
Publicado: (2015)

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development
por: Lu, Yanmei, et al.
Publicado: (2016)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Regulatory Pathway for Licensing Biotherapeutics in Mexico
por: López-Morales, Carlos A., et al.
Publicado: (2018)

Enhanced production of recombinant serratiopeptidase in Escherichia coli and its characterization as a potential biosimilar to native biotherapeutic counterpart
por: Srivastava, Vishal, et al.
Publicado: (2019)

What Constitutes Translational Research? Implications for the Scope of Translational Vision Science and Technology
por: Zarbin, Marco
Publicado: (2020)

The Importance of Reviewers
por: Zarbin, Marco
Publicado: (2016)

The Elusive Nature of Truth in Scientific Studies and the Importance of Peer Review
por: Zarbin, Marco
Publicado: (2018)

The Importance of Reviewers
por: Zarbin, Marco
Publicado: (2017)

The Elusive Nature of Truth in Scientific Studies and the Importance of Peer Review
por: Zarbin, Marco
Publicado: (2022)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

Integrated BioTherapeutics
por: Aman, M. Javad
Publicado: (2018)

Artificial Intelligence: Quo Vadis?
por: Zarbin, Marco A.
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023)

The Elusive Nature of Truth in Scientific Studies and the Importance of Peer Review
por: Zarbin, Marco, et al.
Publicado: (2023)

Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability
por: Trikeriotis, Markos, et al.
Publicado: (2022)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016)

The Emerging Biotherapeutic Agent: Akkermansia
por: Kalia, Vipin Chandra, et al.
Publicado: (2021)

Editorial: Characterization of biotherapeutic products
por: Rathore, Anurag S., et al.
Publicado: (2022)

Biosimilars as a strategy to improve sustainability
por: Bria, Emilio, et al.
Publicado: (2017)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

Biologics and biosimilars: what, why and how?
por: Chan, Juliana CN, et al.
Publicado: (2017)

Biosimilars: Promises Made. Promises Kept?
por: Martinez-Cabriales, Sylvia A., et al.
Publicado: (2021)

There Is No Substitute for Effective Education About Biosimilars
por: Maltz, Ross M, et al.
Publicado: (2021)

Aggregation risk prediction for antibodies and its application to biotherapeutic development
por: Obrezanova, Olga, et al.
Publicado: (2015)

The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development
por: Doocey, Claire M., et al.
Publicado: (2022)

Development of mucoadhesive adapalene gel for biotherapeutic delivery to vaginal tissue
por: Afzaal, Hasan, et al.
Publicado: (2022)

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023)

How can we discover developable antibody-based biotherapeutics?
por: Bauer, Joschka, et al.
Publicado: (2023)

Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011)

Biosimilar insulins: Informed choice for South Asia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017)

Fármacos biológicos y biosimilares: aclarando conceptos
por: Rodriguez Cumplido, Dolores, et al.
Publicado: (2018)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Expanding Footprints of Biosimilar Tenecteplase
por: Subhash, et al.
Publicado: (2023)

Cyanobacterial Production of Biopharmaceutical and Biotherapeutic Proteins
por: Betterle, Nico, et al.
Publicado: (2020)

Pediatric Dosing and Body Size in Biotherapeutics
por: Shi, Rong, et al.
Publicado: (2010)

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
por: Husain, Bushra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_80lsjdu4hgd8j98eidu7iggjbf